-transparent.png){kind=logo}
Our studies demonstrate that in the explanation of the protective effect of the calcium antagonist (S)-emopamil the possibility of beneficial metabolic causes (lower O2 consumption) must also be considered beside of blood flow increasing effects. It is suggested that (S)-emopamil may be a useful drug for the treatment of cerebro-ischemic disorders.
Related Publications
A G Kovách, and
L T Nguyen, and
L Pék, and
L Dezsi, and
Z S Lohinai
August 1987,
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism,
A G Kovách, and
L T Nguyen, and
L Pék, and
L Dezsi, and
Z S Lohinai
March 1989,
Arzneimittel-Forschung,
A G Kovách, and
L T Nguyen, and
L Pék, and
L Dezsi, and
Z S Lohinai
January 1984,
Acta physiologica Hungarica,
A G Kovách, and
L T Nguyen, and
L Pék, and
L Dezsi, and
Z S Lohinai
August 1988,
The Journal of pharmacology and experimental therapeutics,
A G Kovách, and
L T Nguyen, and
L Pék, and
L Dezsi, and
Z S Lohinai
January 1988,
Critical care medicine,
A G Kovách, and
L T Nguyen, and
L Pék, and
L Dezsi, and
Z S Lohinai
March 1987,
Journal of neurosurgery,
A G Kovách, and
L T Nguyen, and
L Pék, and
L Dezsi, and
Z S Lohinai
January 1990,
Advances in neurology,
A G Kovách, and
L T Nguyen, and
L Pék, and
L Dezsi, and
Z S Lohinai
October 1992,
Journal of neurosurgery,
A G Kovách, and
L T Nguyen, and
L Pék, and
L Dezsi, and
Z S Lohinai
January 1974,
Pflugers Archiv : European journal of physiology,
A G Kovách, and
L T Nguyen, and
L Pék, and
L Dezsi, and
Z S Lohinai
October 1997,
Masui. The Japanese journal of anesthesiology,
